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ABSTRACT: Rett syndrome (RTT) is a neurodevelop-
mental disorder with one principal phenotype and sev-
eral distinct, atypical variants (Zappella, early seizure on-
set and congenital variants). Mutations in MECP2 are
found in most cases of classic RTT but at least two ad-
ditional genes, CDKL5 and FOXG1, can underlie some
(usually variant) cases. There is only limited correla-
tion between genotype and phenotype. The Rett Net-
worked Database (http://www.rettdatabasenetwork.org/)
has been established to share clinical and genetic informa-
tion. Through an “adaptor” process of data harmonization,
a set of 293 clinical items and 16 genetic items was gen-
erated; 62 clinical and 7 genetic items constitute the core
dataset; 23 clinical items contain longitudinal information.
The database contains information on 1838 patients from
11 countries (December 2011), with or without mutations
in known genes. These numbers can expand indefinitely.
Data are entered by a clinician in each center who su-
pervises accuracy. This network was constructed to make
available pooled international data for the study of RTT
natural history and genotype–phenotype correlation and
to indicate the proportion of patients with specific clinical
features and mutations. We expect that the network will
Additional Supporting Information may be found in the online version of this article.
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serve for the recruitment of patients into clinical trials and
for developing quality measures to drive up standards of
medical management.
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Introduction
Rett syndrome (RTT; MIM# 312750) is a neurodevelopmental
disorder, which becomes recognizable at 6–12 months [Neul et al.,
2010]. In the majority of cases (99.5%), the disease is sporadic. At
least four phenotypic variants have been described: (1) the more
common classic form described by Rett in the 1960s [Rett, 1966];
(2) the less common preserved speech variant described by Zappella
in the 1990s [Zappella, 1992]; (3) the rare early onset seizure variant
[Hanefeld, 1985]; and (4) the very rare congenital variant [Rolando,
1985]. The penetrance is nearly complete. A few unaffected gene car-
riers have been described, who usually have skewed X-chromosome
inactivation and are recognized as the healthy mothers of two af-
fected siblings.
RTT is a rare disease, with incidence estimated at 1:10,000
[Leonard et al., 1997]. However, due to the high clinical variability,
the disease frequency could be underestimated. The diagnosis of the
mildest form, the Zappella variant, could be particularly challenging
for nonexpert clinicians and these girls could be often misdiagnosed
C© 2012 WILEY PERIODICALS, INC.
Table 1. Harmonization of 1 Out of 293 Clinical Items: The Example of “Head Score”
Barcelona Rett Database British Isles Rett Syndrome Survey (BIRSS)
Italian Rett Database























1 = deceleration of
head growth
yes percentile > 10 1 = deceleration of
head growth
yes percentile 3–10
No No 2 = no evidence of fall from
original centile
0 = no deceleration no 0 = no deceleration
OFC: Occipitofrontal circumference.
as autistic patients. In addition, sudden death in young still undiag-
nosed patients may also contribute to under reporting.
Classic RTT is characterized by a period of regression with the loss
of purposeful hand use and spoken language and the development
of gait abnormalities and hand stereotypies. After the regression,
a stage of stabilization and potentially even improvement ensues,
with some individuals partially regaining skills.
Atypical RTT syndrome is also characterized by a period of re-
gression followed by recovery or stabilization, but the course of
this form is dramatically different. The Zappella (preserved speech)
variant is characterized by better preserved hand use, the recovery
of some language after regression with the ability to use single words
or phrases, and less severe intellectual disability (IQ up to 50). The
early onset seizure variant is characterized by onset of seizures before
5 months of age, before regression usually commences, and often
with frequent infantile spasms and refractory myoclonic epilepsy.
The congenital variant is characterized by severe psychomotor de-
lay from birth, severe postnatal microcephaly apparent before 4
months, and regression in the first 5 months.
This overlapping but wide clinical spectrum of diseases may re-
sult from mutations in one of three genes. In 1999, Amir et al.
first found RTT caused by MECP2 gene (MIM# 300005) mutations
[Amir et al., 1999]. In 2000, De Bona et al. found that the same gene
was mutated in the Zappella variant [De Bona et al., 2000]. MeCP2 is
a transcriptional regulator of specific genes and microRNAs. Phos-
phorylation of its C-terminal part leads to transcriptional induction
of BDNF (MIM# 113505), dendrite branching, and neuronal mat-
uration. Scala et al. reported CDKL5 (MIM# 300203) mutations
associated with the early onset seizure variant [Scala et al., 2005].
CDKL5 is a kinase that associates in vivo with MeCP2 and medi-
ates its phosphorylation in vitro. In 2008, the FoxG1 gene (MIM#
164874) was identified as a cause of the congenital variant form
[Ariani et al., 2008]. FOXG1, like MECP2, is a transcriptional regu-
lator that is expressed specifically in brain.
Several RTT databases have been established. The first one,
RettBASE (http://mecp2.chw.edu.au/), collected predominantly
molecular genetic data and includes mutations reported in English-
language peer-reviewed journals and data generated by the Aus-
tralian cohort of RTT patients [Christodoulou et al., 2003]. The
other databases include both clinical and genetic data. One of them,
InterRETT [Fyfe et al., 2003] was based on data collection by dis-
tributing a questionnaire to the families [Fyfe et al., 2001]. Most of
the other databases operate within one country and are supervised
by clinicians. The Italian Rett Database and Biobank included 357
patients and had 20 structured and 7 descriptive clinical items, and
17 structured genetic items (http://www.biobank.unisi.it) [Sampieri
et al., 2007]. The SYRENE (SYndrome REtt NEtwork) included 232
French Rett patients and had 81 structured and 1 descriptive clinical
item, and 12 structured genetic items (http://afsr.in2p3.fr/RETT/).
The British Isles Rett Syndrome Survey (BIRSS) included 275 British
Rett patients and had 271 structured and 94 descriptive clinical
items, and 6 structured genetic items; it included also longitudinal
data. The Barcelona Rett database included 388 Spanish Rett pa-
tients and had 44 structured and 4 descriptive clinical items, and 4
structured genetic items. Finally, a recent American survey collected
data on the natural history of the disease [Percy et al., 2007]. Using
an “adaptor approach” that allowed the preservation and integra-
tion of the original data, we have established the Rett Networked
Database (http://www.rettdatabasenetwork.org/), designed to be a
unified data repository allowing researchers and physicians to access
comprehensive patient information.
Database Network Structure
Rett Networked Database Data Harmonization
The Rett Networked Database is a comprehensive, permis-
sive, and flexible unified structure available online at http://www
.rettdatabasenetwork.org/. To build it, a data harmonization pro-
cess was required. Hundreds of items have been analyzed and
a common database schema has been defined and approved by
the Scientific Review Board (Appendix). To give an idea of the
harmonization process, Table 1 shows the example of the item
“Head score” in the domain “Head” (Table 1). This item is one
of the 293 clinical items and 16 genetic items that were generated
through a data harmonization process (Supp. Table S1, column
B). All these items were grouped in 31 domains (Supp. Table S1,
column A).
Rett Networked Database Minimum Data Set
In March 2010, the Scientific Review Board of Rett Networked
Database met in Paris and established a minimum data set, which
has been reviewed and integrated on August 18, 2011. It consists of
63 clinical items and 7 genetic items (Supp. Table S1, column B, gray
values). The specific values of each of these items are illustrated in
Supp. Table S1, column C.
Regarding the genetic items, mutation names comply with the
accepted guidelines proposed by the Human Genome Variation
Society (www.hgvs.org/mutnomen) [den Dunnen and Antonarakis,
2000].
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Figure 1. Types of values of the items. A: Example of a static drop-down menu for item “weight score” and of a longitudinal item “weight with
age (gr)” in the “weight” domain. B: Example of values present in the “regression” domain: numerical field value “regression age (months)” and
text field value “behavioral disturbance” C: Example of yes/no drop-down menu for the item “mutation in a gene” and a dynamic drop-down menu
for the item “mutated gene,” present in the “genetic data” domain.
Rett Networked Database Web Server Interface
Implementation
The Rett Networked Database Web server is intended to facil-
itate the access to the data stored in the database and to provide
tools for its analysis. The Web server interface consists of HTML
pages dynamically generated using VBScript and Active Server Pages
(ASP) technologies. The scripting programs run on an Internet
Information Server and use the MySQL (http://www.mysql.com)
relational database system.
The Web site was shaped in such a manner that on the first
page only the minimum data set of items is displayed. Within each
group of items (each domain), more detailed entries accommodate
the total of 293 clinical and 16 genetic items. All the items are
grouped in 31 domains (30 clinical and 1 genetic). The values of
most items (192/309, 62%) are assigned by a drop-down menu.
Most of the drop-down menus have two (yes/no) or three values
as, for example, for “Weight score” (1) below 3rd percentile; (2)
3rd to 25th percentile; and (3) above 25th percentile (Fig. 1A). In
some cases (51/309, 17%), the value is a number as in the case
of “occipitofrontal circumference (OFC) at birth in centimeters”
or “Regression age in months” (Fig. 1B). In 64 out of 309 (21%),
the value is represented by a text field such as “Regression speech
Note” or “Behavioral Disturbances” (Fig. 1B). A group of 23 clinical
items contains longitudinal information. The values of 3 out of 16
genetic items, namely, “Mutated gene”, “Nucleotide change” and
“AA change” are assigned by a dynamic drop-down menu (Fig. 1C).
Values are inserted as a text field that generates a drop-down menu.
The data are accessible to the participants through the use of a
protected password. In addition, data are accessible to the scien-
tific community according to rules that guarantee transparency and
equity. There are three different levels of access: (1) Public access.
General information and the description of the database content is
available to the public; (2) Aggregated data access. Registered users
have access to aggregated data only. Registered users have to disclose
their identity and affiliation and have to agree to the data protection
policy (Human Biobanks and Genetics Research Databases guide-
lines); (3)Full access. Access to individual data and statistical analysis
is given upon the submission of a research proposal to the Scien-
tific Review Board composed of the major contributors (Appendix).
The Scientific Review Board may decide the conditions of access, for
example, scientific collaboration or acknowledgment or citation of
the paper that describes the database (key contributors will be coau-
thors). The approval of the local research ethics committee of the
University of the Coordinator of the database will be required too.
Rett Networked Database Data Storage
The database network was created following an “adaptor ap-
proach.” This approach allowed us to preserve the original data as
stored in each contributing database and to integrate them in a
comprehensive, permissive, and flexible unified structure. The sys-
tem uses a set of predefined import procedures to extract, decode,
and convert data from preexisting databases and to insert them into
the new, central database so that the new archive represents a unified
repository (Fig. 2).
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Figure 2. Scheme representing Rett Networked Database. In the central part of the figure, the dynamically generated Web server interface is
represented. Dark gray arrows: data flow from preexisting databases to the new central one. Light gray arrows: direct data insertion from local
centers.
The data are stored in a MySQL server. The interface has been
developed using a common scripting language (VB/ASP). This ap-
plication allows data storage for users who do not have a local
computerized data management system. In such a case, there are
two options: (1) to insert data directly into the main archive (ge-
ographical and institutional identifications will be displayed); or
(2) to construct a local or national archive to be connected with
the main one. The archive is permissive so that patients with only
partially filled items can be inserted. For users who have an active
national database, periodic data update is performed by an infor-
mation interchange system.
Maintenance- and hardware/software-qualified assistance are
guaranteed by an informatic structure 24 hr a day and 7 days a
week. The structure ensures availability and redundancy of con-
nectivity, immediate power supply in case of energy interruption,
constant temperatures and humidity within the data rooms, and
security to avoid unauthorized access. Furthermore, data security is
ensured by scheduled backups.
Rett Networked Database Analysis Tools
Basic data mining operations have been applied that cut across
applications and develop scalable algorithms for their execution. The
data mining interface is developed to ensure maximum flexibility so
that users can perform any search they want. This approach allows
them to better identify novel genotype–phenotype correlations, to
better select subgroups of patients for clinical trials, and to improve
the efficiency of the modifier genes study.
Data mining is possible using the “search” button placed in the
homepage after the log in (Fig. 3). It is possible to search for patients
within the whole archive or to select a specific country or center.
Patient data can be searched for features in 46 items belonging to 25
different domains (e.g. head, height, etc.) of the minimum data set.
It is possible to perform multiple searches at once. The maximum
number of items that can be selected simultaneously is 10.
Rett Networked Database Present Shape
Beside the data imported from the four preexisting databases,
several other countries started to insert patients directly in the net-
work: Israel (60 patients), Croatia (26 patients), Serbia (44 patients),
Denmark (64 patients), Hungary (58 patients), and Romania (9 pa-
tients). Furthermore, an additional local database consisting of 96
patients has been connected (Tri-State Rett Syndrome Center, New
York). Additional requests to join the network have been made by
Germany, Sweden, and Finland.
As of December 2011, this database contains detailed clinical and
molecular information on 1838 patients, representing the largest
cohort of RTT patients collected up to now.
Among them, 1252 have mutations in MECP2, 64 in CDKL5, 6
in FOXG1. Among the MECP2 mutations, 40% introduce an amino
acid change in either methyl binding domain or transcriptional re-
pressor domain (TRD), 39% an early premature termination codon
before the TRD domain, 14% a late premature termination codon
after TRD domain, and 7% are gene deletions. Regarding CDKL5
mutations, 37% introduce an amino acid change in the catalytic
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Figure 3. The “search tool.” A: Example of research of patients from the whole archive having specific values for five items (RettDiagnosed,
headscore, Ageatepilepsy, MutatedGene, AAChange) belonging to eight domains (personal data, Rett diagnosed, family data, pregnancy and
delivery, head, weight, epilepsy, genetic data) (modified from the longer list available at www.rettdatabasenetwork.org/Search.asp). By clicking
on the “next” button, a second page, where specific values for the selected items can be chosen, is visualized (B). By clicking on the “search”
button, the system will return the total number and the list of all patients fulfilling the selected criteria.
domain, 26% an early premature termination codon within the cat-
alytic domain, 25% a late premature termination codon after the
catalytic domain, and 12% are gene deletions. Regarding FOXG1
mutations, most of them introduce an early premature termination
codon before the fork-head domain.
Discussion
The Rett Networked Database was created in order to connect
those databases already in existence and to create a unified data
repository following an “adaptor approach.” The Rett Networked
Database now allows the collection of standardized and easily com-
parable clinical and genetic data of a large number of Rett pa-
tients, representing the largest collection worldwide, and it avoids
the dissemination of information on many different databases. This
network represents a unique attempt to create a connection of locus-
specific databases that for many rare diseases remain dispersed, and
distinct and we would expect that other locus-specific databases will
follow the same approach in the future.
Presently, 14 centers from 11 countries of Europe, the Middle
East, and the United States are connected in the network. Data are
entered by each center by a clinician who supervises the accuracy of
stored information. This characteristic makes the network unique
in the sense that each patient can be contacted anytime for clinical
update and research or clinical studies.
Although patients are anonymized, the system is able to recognize
if clinicians attempt to insert the same patient twice. In such a case,
the system stops the “new” reinsertion and permits the updating
of a patient’s data even if the patient has originally been entered
by another center, preserving original data. This mechanism will
be particularly useful when more centers from the same country
participate in the network, while this is less likely at present.
The system is comprehensive, including 309 items (293 clinical
and 16 genetic) grouped in 31 domains (30 clinical and 1 genetic).
The values of most items (62%) are assigned by a drop-down menu
with two (yes/no) or three values. In some cases (17%), the value is
a number indicating a measure or an age. In as few items as possible
(21%), the value is represented by a text field since these are less
useful for statistical analysis. A consistent number of clinical items
(23) contain longitudinal information that would be particularly
useful if the network was being used for clinical trials.
The system is also easily scalable allowing additional
items/domains to be added in the future. At the beginning of the
harmonization process, the values present in the drop-down menu
for the item “age at epilepsy onset” did not include the range 0–1
year. Shortly after the inclusion of the CDKL5 patients, the need
to add the additional value 0–1 year was felt and the system easily
allowed this change.
Finally, the system is permissive since patients with incomplete
data can be inserted, although at least the minimum dataset (70
items: 63 clinical and 7 genetic) is recommended. In case of a first
evaluation, a clinician can immediately insert clinical data without
genetic data that will be updated later on.
Access to the network is open to other, already existing databases
worldwide that choose to join. The new archive represents a unified
repository, in which additional national or local cohorts of patients
may be inserted. The network started in 2009 with five centers (5
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countries), grew to 11 (8 countries) in 2010, and to 14 (11 countries)
in 2011; and given this trend, we anticipate further expansion.
Data are accessible to the participating database contributors (Ap-
pendix) and to the scientific community according to rules that
assure transparency and equity. Data access will allow registered
users to quickly and easily share novel information. This database
will be of great help in diagnosing the disease and genetic coun-
seling and will lead to novel insights, especially in the rare clinical
variants concerning which there is often a lack of specific knowl-
edge and experience. This database might also be of assistance when
interpreting a novel genetic variant.
Data from the Rett Networked Database are available for the inter-
national community for (1) further natural history studies and (2)
further genotype–phenotype studies. In addition, these data may be
used: (3) to give an indication as to the proportion of patients of dif-
ferent ages who have specific symptoms (and who might therefore be
interested in treatments targeting those symptoms) and minimum
numbers of affected individuals who have specific mutations (and
therefore for whom particular treatments might be applicable); (4)
to identify which centers might therefore be useful for recruiting
specific groups of patients (e.g., for clinical trials). Finally, another
use could be: (5) to develop quality of care measures that would be
useful to drive up standards of medical management.
In conclusion, this international effort will be of great value to
both the scientific and the clinical RTT communities. It will se-
cure RTT patients, worldwide, the best continuous research in the
syndrome, which eventually can give them a better quality of life
and it will inspire countries to gather information about their RTT
population, which would further lead to foundation of new RTT
centers.
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Appendix
Scientific Review Board of the Rett Networked Database as of
December 2011: Alessandra Renieri (Coordinator), Francesca Mari
(University of Siena, Siena, Italy), Laurent Villard (Universite´ de la
Me´diterrane´e and Inserm, Marseille, France), Nadia Bahi-Buisson
(University Paris V Descartes, Paris, France), Angus Clarke, Anna
Hryniewiecka-Jaworska (Cardiff University, Wales, U.K.), Mercedes
Pineda, Ana Roche Martinez, Judith Armstrong (Hospital Sant Joan
de De´u, Barcelona, Spain), Bruria Ben-Zeev (Sheba Medical Cen-
ter, Ramat-Gan, Israel). Members as of December 2011: Edvige
Veneselli, Maria Pintaudi (University of Genova, Genova, Italy), Sil-
via Russo, Francesca Cogliati (Istituto Auxologico Italiano, Milan,
Italy), Aglaia Vignoli (Ospedale San Paolo, Milano, Italy), Giorgio
Pini (Versilia Hospital, Viareggio, Italy), Milena Djuric (Univer-
sity of Belgrade, Belgrade, Serbia), Anne-Marie Bisgaard (Glostrup,
Denmark), Kirstine Ravn (Glostrup, Denmark), Vlatka Mejasˇki-
Bosˇnjak (University of Zagreb, Zagreb, Croatia), Be´la Melegh, Polga´r
Noe´mi (University of Pe´cs, Pe´cs, Hungary), Dana Craiu (Carol
Davila University of Medicine, Bucharest, Romania), Aleksandra
Djukic (Montefiore Medical Center, Albert Einstein College of
Medicine, New York). At present, this last center contributed only
with anonymous genetic data. Clinical data will be inserted as soon
as the Institutional review board approval will be obtained.
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